<DOC>
	<DOCNO>NCT01933568</DOCNO>
	<brief_summary>A phase I trial conduct patient inoperable locally advanced NSCLC treat combination Conventional Fractionated Radiotherapy ( CFRT ) mediastinal lymph node Stereotactic Ablative Radiotherapy ( SABR ) primary tumor concurrent chemotherapy . It hypothesize lead increase local control overall survival</brief_summary>
	<brief_title>Combined CFRT SABR Stage II III NSCLC With Peripheral Tumors Smaller Than 5 cm .</brief_title>
	<detailed_description>In locally advanced NSCLC local control poor , SABR remarkable high local control rate low toxicity report . Currently stage III inoperable II NSCLC patient treat IMRT concurrent chemotherapy institute . In study explore combination SABR CFRT concurrent chemotherapy</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Cytological histological proven NSCLC stage III inoperable stage II , cT12a3N13M0 peripheral tumor &lt; 5 cm ( chest wall infiltration exclusion criterion tumor diameter &lt; 5 cm ) . Weight loss &lt; 10 % last three month WHOperformance status â‰¤ 2 Patients receive concurrent chemoradiotherapy , exception adriamycin gemcitabine FEV1 DLCO &gt; 40 % ageadjusted normal value Minimum require laboratory data bone marrow reserve hepatic renal function Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Before patient registration , write informed consent must give accord GCP national regulation Exclusion criterion : Patients central tumor &lt; 2 cm proximal bronchial tree ( Figure 2 ) tumor immediately adjacent mediastinal pericardial pleura . Patients receive sequential chemoradiotherapy radiotherapy . Patients grade 3 dyspnea baseline ( accord CTCAE version 4.03 ) Patients Pancoast tumor Prior radiotherapy treatment thorax Any contraindication administration thoracic radiotherapy Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>